Small-Scale Dosimetry: Challenges and Future Directions
Section snippets
MIRD Method
In 1968, the MIRD Committee established the formalism for dose calculation from internally deposited radionuclides reducing the complex nature of the absorbed dose calculation into a simple mathematical form.10 The MIRD schema provides methods for calculating the absorbed dose from the source-activity distribution and the physical properties of the radionuclide. This calculation is simply the conversion of activity in a source organ into the energy absorbed per unit mass in the target organ. In
Beta Particles
Beta emitters have been used for several decades within the context of targeted radiotherapy.1 Even though 131I is still the beta emitter most used within that context, 90Y has also been widely used, for example, in RIT of non-Hodgkin lymphoma.2 Several beta emitters have been investigated as potential candidates for targeted radiotherapy47; however, as stated in an early report by Rogus and Wessels,48 dosimetric behavior is just one criterion among many governing the selection of a particular
Alpha Particles
In recent years, a number reports have characterized the use of alpha particle emitters in therapeutic applications.3, 4, 5, 6, 84, 85, 86 Alpha particles consist of a helium nucleus with a charge of + 2, and are often the result of the decay of nuclei with an atomic number (Z) greater than 82.49 Symbolically, the decay is expressed as: where α represents the alpha particle and γ is a gamma emission that often accompanies the decay.49 The alpha particles considered for therapy
Auger Electrons
There are many radionuclides that decay by a process known as electron capture. Electron capture is a beta decay process that competes with positron emission. For nuclei, which are unstable because of an excess of positive charge, this positive charge can be reduced by the transformation of a proton to a neutron with the emission of a positron, or alternatively by nuclear capture of an orbital electron.49 Whereas there are no emissions directly from the nucleus, the residual inner
Summary
The principles of small-scale dosimetry for alpha particle, beta particle and Auger electron emitting radionuclides have been in existence for several years. These calculational techniques have been applied to a number of studies – theoretical, in vitro and to a lesser amount, in vivo. Two general calculational approaches have been used. Analytical methods are based on equations that parameterize the energy deposited from individual source emissions.20, 51, 52, 88 These calculations are fast
References (152)
- et al.
Radionuclide therapy
Lancet
(1999) - et al.
Targeted alpha particle immunotherapy for myelosis leukemia
Blood
(2002) A microdosimetric model of astatine-211 labeled antibodies for radioimmunotherapy
Int J Radiat Oncol Biol Phys
(1987)- et al.
Three-dimensional tumor dosimetry for radioimmunotherapy using serial autoradiography Int
J Radiat Oncol Biol Phys
(1992) - et al.
Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody
J Nucl Med
(2002) - et al.
Preclinical studies of targeted alpha therapy for breast cancer using 213Bi-labelled-plasminogen activator inhibitor type 2
Br J Cancer
(2003) - et al.
Intralesional targeted alpha therapy for metastatic melanoma
Cancer Biol Ther
(2005) - et al.
First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases
Clin Cancer Res
(2005) - et al.
Increased nuclear damage by high linear energy transfer radioisotopes applicable for radiodirected therapy against radiologic malignancies
Gynecol Obstet Invest
(1991) - et al.
Radiotoxicity of iodine-125 and other auger-electron-emitting radionuclides: Background to therapy
Cancer Biother Radiopharm
(2003)